Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma Membrane Na⁺-Coupled Citrate Transporter (SLC13A5) and Neonatal Epileptic Encephalopathy.

Molecules (Basel, Switzerland) - 28 Feb 2017

Bhutia Yangzom D, Kopel Jonathan J, Lawrence John J, Neugebauer Volker, Ganapathy Vadivel

Abstract excerpt

SLC13A5 is a Na⁺-coupled transporter for citrate that is expressed in the plasma membrane of specific cell types in the liver, testis, and brain. It is an electrogenic transporter with a Na⁺:citrate3- stoichiometry of 4:1. In humans, the Michaelis constant for SLC13A5 to transport citrate is ~600 μM, which is physiologically relevant given that the normal concentration of citrate in plasma is in the range of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain
Share to Citric Acid
Share to Infant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infant, Newborn

Share to Spasms, Infantile

Share to Symporters

Share to Testis

Source

Open in PubMed Open full text

Identifiers

PMID: 28264506
DOI: 10.3390/molecules22030378
PMCID: PMC6155422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma Membrane Na⁺-Coupled Citrate Transporter (SLC13A5) and Neonatal Epileptic Encephalopathy.PMID 28264506Read ↗

Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier.Semantic proximity Read ↗

AAV-mediated gene therapy for SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypesSemantic proximity Read ↗

Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life.Semantic proximity Read ↗

Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia.Semantic proximity Read ↗

Molecular phenotypes segregate missense mutations in SLC13A5 EpilepsySemantic proximity Read ↗

Molecular Phenotypes Segregate Missense Mutations in SLC13A5 Epilepsy.Semantic proximity Read ↗

AAV-mediated gene therapy in a model of SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes.Semantic proximity Read ↗

Large-scale experimental assessment of variant effects on the structure and function of the citrate transporter SLC13A5Semantic proximity Read ↗

Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism.Semantic proximity Read ↗

Epileptic phenotypes in <i>slc13a5</i> loss-of-function zebrafish are rescued by blocking NMDA receptor signalingSemantic proximity Read ↗

SLC13A5 Deficiency Disorder: From Genetics to Gene Therapy.Semantic proximity Read ↗

Role of Sodium dependent SLC13 transporter and its inhibitors in various metabolic disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.